Table 1.

	Crude Accelerators	95%CI	p-value†	Adjusted Accelerators	95%CI	p-value†
Age category at start of TB treatment			0.008
≥ 40 (baseline)	1
25-39	1.12	1.04 - 1.21	0.003
18-24	1.15	1.02 - 1.30	0.022
Gender
Male	1
Female (baseline)	1.01	0.94 - 1.07	0.879
Clinic			<0.001			<0.001
2 (baseline)	1			1
1	1.08	1.00 - 1.15	0.046	1.39	1.29 - 1.48	<0.001
3	1.34	1.21 - 1.48	<0.001	1.56	1.42 - 1.71	<0.001
Year started TB treatment			<0.001			<0.001
2002-2004 (baseline)	1			1
2005	1.08	0.98 - 1.18	0.111	1.08	0.99 - 1.19	0.079
2006	1.34	1.23 - 1.46	<0.001	1.22	1.12 - 1.33	<0.001
2007-2008	1.83	1.65 - 2.03	<0.001	1.39	1.25 - 1.54	<0.001
CD4 count categories* (cells/μL)			<0.001			<0.001
>=200 (baseline)	1			1
100-199	1.16	1.03 - 1.32	0.017	1.20	1.07 - 1.34	0.002
50-99	1.29	1.14 - 1.47	<0.001	1.34	1.19 - 1.50	<0.001
0-49	1.70	1.49 - 1.94	<0.001	1.75	1.55 - 1.98	<0.001
Classification of TB
Rtetreatment (baseline)	1
New TB case	1.11	1.03 - 1.19	0.004
Type of TB			0.018
Smear-Negative Pulmonary TB (baseline)	1
Extra-Pulmonary TB	1.05	0.97 - 1.13	0.262
Smear-Pbstive Pulmonary TB	1.12	1.04 - 1.22	0.005

^†The p-value in line with the heading of each variable with more than 2 categories wascalculated using the Waid Test

^*CD4 count taken closest start of TB treatment that satisfied criteria of being taken not earlier than 183 daysbefore or 91 daysafter start of TB treatment and not more than 7 days after start of ART

Shape parametersof multivariate gamma model: kappa = 0.7 (95%CI: 0.57-0.84); sigma = 0.42 (95%CI: 0.39-0.45) for all strata other than CD4count lessthan 50 cells/μL(sgma = 0.59, 95%CI:0.50-0.69) and clinic 1 (sigma = 0.51, 95%CI: 0.44-0.60)